Literature DB >> 33625633

Why We Still Need the Better Risk Classification for GIST.

Piotr Rutkowski1.   

Abstract

Year:  2021        PMID： 33625633     DOI： 10.1245/s10434-021-09620-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  2 in total

1.  Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.

Authors:  Agnieszka Wozniak; Piotr Rutkowski; Patrick Schöffski; Isabelle Ray-Coquard; Isabelle Hostein; Hans-Ulrich Schildhaus; Axel Le Cesne; Elzbieta Bylina; Janusz Limon; Jean-Yves Blay; Janusz A Siedlecki; Eva Wardelmann; Raf Sciot; Jean-Michel Coindre; Maria Debiec-Rychter
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

2.  Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.

Authors:  Chandrajit P Raut; N Joseph Espat; Robert G Maki; Dejka M Araujo; Jonathan Trent; Toni Faith Williams; D Das Purkayastha; Ronald P DeMatteo
Journal:  JAMA Oncol       Date:  2018-12-13       Impact factor: 31.777
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.